Drug Profile


Alternative Names: Coronavirus DNA vaccine - VRC/NIAID; SARS DNA vaccine - VRC/NIAID; SARS recombinant DNA plasmid vaccine - VRC/NIAID; Severe acute respiratory syndrome DNA vaccine - VRC/NIAID

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Vaccine Research Center
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Coronavirus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Coronavirus-infections(Prevention) in USA (IM)
  • 09 Dec 2008 Immunogenicity & adverse events data from a phase I trial for Severe acute respiratory syndrome (SARS) released by Vical
  • 09 Dec 2008 The National Institutes of Health (USA) transfers IND for its SARS DNA vaccine in phase I trials to Vical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top